36 results about "Hematoporphyrin" patented technology

A resin composition with a high crystallization rate that contains a polyalkylene furan dicarboxylate resin and a porphyrin compound, and a molded article composed of the resin composition. The polyalkylene furan dicarboxylate resin is preferably a polybutylene furan dicarboxylate resin. The porphyrin compound is preferably hematoporphyrin dihydrochloride. The molded article is obtained by molding the resin composition.

A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (''DMSO''); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with diabetes and obesity.

The invention discloses an oxygen-carrying and drug-loading self-assembled nano-drug with molecular targeting/sonodynamic therapy (SDT) and a preparation method thereof. According to the nano-drug, erlotinib-modified chitosan (CE) is used as a carrier, then hematoporphyrin (HP) and perfluorooctane bromide (PFOB) are loaded, and CE/PFOB/HP self-assembled nanoparticles (CEPH) are prepared through self-assembly. As a sound sensitizer, the HP can play a role in SDT; and the PFOB carries oxygen and can improve the microenvironment of tumor relative to hypoxia, enhance the SDT effect and overcome the drug resistance of tumor cells to a chemotherapeutic drug Er (erlotinib) under the hypoxia condition. According to the nano-drug, molecular targeted therapy and SDT are combined, the PFOB is used for reversing drug resistance, and tumor cell proliferation can be inhibited to the maximum extent through cooperation of molecular targeted therapy, SDT and PFOB.

The invention discloses a technique for improving phototoxicity effect of hematoporphyrin photosensitizers on tumor cells by preparing the hematoporphyrin photosensitizer/cationic hyperbranched polysaccharide derivative composite nanoparticles. The composite nanoparticles have the following characteristics and have great application prospect in the field of efficient and safe treatment of tumors through photodynamic: 1) the composite nanoparticles have relatively high tumor cell killing efficiency when the concentration of the hematoporphyrin photosensitizers is relatively low, reduction of the dosage of the hematoporphyrin photosensitizers is facilitated, and the safety of the hematoporphyrin photosensitizers for normal cells and tissue under light irradiation is improved; 2) the composite nanoparticles with the particle size ranging from 200 nm to 250 nm have a passive targeting property for tumor tissue, and the safety of the hematoporphyrin photosensitizers for normal cells and tissue is improved; 3) the composite nanoparticles have the electropositivity, can carry the hematoporphyrin photosensitizers to cross over electronegative cell membranes to enter tumor cells, and accordingly, the endocytosis efficiency of the tumor cells for the hematoporphyrin photosensitizers is improved; 4) the preparation condition is mild, the process is simple, the operation is convenient and the cost is low.

The invention discloses a pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide ('DMSO'); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively resolve scar tissue, particularly scar tissue resulting from a burn, and to treat patients with bum-related injuries.

A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used effectively to stimulate periapical bone regeneration and for the endodontic treatment of periapical bone abscess, and fibromas, in a patient.

The invention provides a metal hematoporphyrin diether/diester compound and a preparation method thereof. A central metal M of the metal hematoporphyrin diether/diester compound is Fe, Co or Ni. The invention also provides a catalyst for preparing cyclohexane in a catalytic oxidation method and a method for preparing cyclohexane in a catalytic oxidation method by using the catalyst.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of a supramolecular organic framework material to a medicine for removing photodynamic therapy residues. The supramolecular organic framework material is a nano-particle-size water-soluble positive ion type supramolecular organic framework material (SOFs) which is formed by tetrahedral molecules and CB [8] in a water phase through host-guest interaction, and the supramolecular organic framework material realizes high-strength combination and efficient absorption on negatively charged photodynamic therapy medicines (such as chlorin (Ce6), hematoporphyrin (HMTP) and porfimer sodium (Photofrin)). Animal experiments prove that the supramolecular organic framework material can significantly reduce the cumulant of the photodynamic therapy medicine on the surface of animal skin, effectively inhibit the photosensitization of the photodynamic therapy medicine after being irradiated by sunlight, and solve the problem that a patient needs to keep out of light for a long time after photodynamic therapy to a certain extent.

The invention discloses a preparation method of an oxygen-carrying and fluorocarbon chain-modified drug and photosensitizer targeted co-delivery nano-composite and application of the nano-composite to preparation of anti-epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) drug-resistant lung cancer drugs. The preparation method of the nano-composite comprises the steps of performing fluorocarbon chain and EGFR-targeted aptamer (Apt) modification on polyamidoamine (PAMAM) to form a nano-drug delivery carrier APF with oxygen carrying capacity and tumor targeting property, and then co-entrapping photosensitizer hematoporphyrin and molecular targeting drug gefitinib to construct the targeting nano-composite APFHG for enhancing the photodynamic therapy effect. The nano-composite overcomes the defect that photodynamic therapy is limited by a tumor anoxic microenvironment and improves the sensitivity of drug-resistant lung cancer cells to EGFR-TKIs, thereby promoting the combined treatment effect of molecular targeted therapy and photodynamic therapy.

The invention belongs to the field of medicine and pharmacology for increasing sensitivity of chemotherapeutic drugs, and particularly relates to application of a hematoporphyrin-verapamil fragment hematoporphyrin derivative A2 in tolerance reversing and sensitization of breast cancer chemotherapeutic drugs. The hematoporphyrin derivative A2 has different degrees of sensitization of the chemotherapeutic drugs for inhibiting breast cancer cell proliferation, which indicates that the hematoporphyrin derivative A2 can be developed into a sensitizer or a reverse drug-resistant agent of the chemotherapeutic drugs and used for treating breast cancer patients.

The invention belongs to the field of medicine and pharmacology for improving chemotherapy drug sensitivity, and particularly relates to application of a hematoporphyrin-verapamil fragment compound A2in reversing the tolerance and sensitization of chemotherapy drugs for osteosarcoma. Different degrees of the sensitization chemotherapeutic drugs of the compound A2 inhibit the proliferation of osteosarcoma cells, which indicates that the compound A2 can be developed into a sensitizer or a reverse drug resistance of the chemotherapeutic drugs and is used for treating osteosarcoma patients.

The invention belongs to the field of medicines for improving the sensitivity of chemotherapeutic drugs, and particularly relates to application of a hematoporphyrin-verapamil fragment hematoporphyrinderivative A2 in tolerance reversion and sensitivity improvement of a colon cancer chemotherapeutic drug. The hematoporphyrin derivative A2 has the effect of improving the sensitivity of the chemotherapeutic drug for inhibiting the proliferation of colon cancer cells to different degrees, and it is indicated that the hematoporphyrin derivative A2 can be developed into a sensitizer or a drug tolerance reversion agent of the chemotherapeutic drug and is used for treating patients with colon cancer.